Blackstone Life Sciences, a unit of Blackstone Inc., announced a research and development co-funding agreement with Johnson & Johnson to advance clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia. Under the agreement, Johnson & Johnson and funds managed by Blackstone Life Sciences will jointly finance a portion of ongoing and future clinical trials of bleximenib in AML. The announcement referenced promising clinical data, but did not specify whether trial results have already been presented or when future results will be presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blackstone Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.